Andreas Rummelt is Director at ALEXION PHARMACEUTICALS, INC. (ALXN). They have made 6 open-market trades across 1 company since 2010, most recently 2021-07-21.
CIK 0001484986
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $263K since 2010, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ALXN | 27,576 | $5.0M |
Shares reported on the most recent Form 4, priced at the 2021-05-24 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ALXN | SELL | 2014-08-25 | 2014-08-27 | $170.53 | $862K | -15.6% | -1.2% | -1.2% |
| ALXN | SELL | 2012-07-27 | 2012-07-31 | $107.00 | $1.1M | -15.6% | -1.2% | -1.2% |
| ALXN | SELL | 2012-06-07 | 2012-06-08 | $91.29 | $913K | -15.6% | -1.2% | -1.2% |
| ALXN | SELL | 2012-02-21 | 2012-02-23 | $83.36 | $537K | -15.6% | -1.2% | -1.2% |
| ALXN | SELL | 2011-10-24 | 2011-10-25 | $69.01 | $622K | -15.6% | -1.2% | -1.2% |
| ALXN | BUY | 2010-05-10 | 2010-05-12 | $52.60 | $263K | -15.6% | -1.2% | -1.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.